INTRODUCTION
Current treatment techniques are equally effective at eliminating the stenosis in CoA patients. [1] However, a
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good anatomical result does not preclude late systemic hypertension in office visits (12%-65%), [1] [2] [3] [4] [5] [6] at peak exercise (10%-47%), [3] [4] [5] 7, 8] or during ambulatory blood pressure (BP) monitoring (30%-59%). [7] [8] [9] [10] Furthermore, treated patients have reduced life expectancy [ Figure 1 ], [2] mostly due to cardiovascular (CV) complications [2, [11] [12] [13] [14] and stroke. [15] Successfully treated CoA patients have stiffer large arteries [16] [17] [18] [19] [20] [21] and compromised vascular reactivity in small arteries, [8, 10, [22] [23] [24] [25] [26] their arterial pressure waveform is altered, [9, 10, 23, 27, 28] have imbalances in vascular function biomarkers, [24, 25, 27, 29, 30] and increased left ventricular (LV) mass. [8, 9, [19] [20] [21] 26, 31, 32] Vascular dysfunction is associated with older age at treatment, [2, 19, 22, 29, 31, 33] but early treatment does not guarantee normal vascular function. [16, 22] Different treatment modalities may have varying effects on the stiffness of the repaired arterial segment: [34] Surgical repair results in a focal scar in the anastomosis; stenting creates a short, rigid segment; and balloon dilation (BD) produces a controlled tear of the intima and part of the media. Although it is possible that these differences translate into differences in vascular dysfunction, this has not been systematically compared. The largest, albeit observational and nonrandomized, comparison between the three modalities showed a lower BP in patients treated with BD versus those treated with stenting or surgery. [1] A small retrospective study showed less frequent exercise-induced hypertension in BD patients compared with other treatment types. [33] Conclusions drawn from these prior studies are hampered by methodological limitations and limited focus. In the general population, arterial stiffness is associated with major CV events. [35] Thus, choosing the CoA treatment option that optimizes vascular function is crucial for long-term outcomes in CoA.
Aim and hypothesis
The Long-term Outcomes and Vascular Evaluation after Successful Coarctation of the Aorta Treatment study aims to determine whether surgery, BD, and stenting are associated with differences in arterial stiffness in optimally treated patients. Our hypothesis is that patients who underwent successful BD will have better vascular function than patients who underwent successful surgical repair or stenting since this modality may least likely damage the biomechanical properties of the aortic wall.
METHODS

Study overview
This study is a cross-sectional prospective observational study of patients with CoA previously treated using one of three treatment modalities. Patients will be recruited at seven large pediatric cardiac centers from Europe and the United States of America [Appendix 1]. The study procedures will occur in a 1-or 2-day visit [ Figure 2 ].
Recruitment
Selection criteria are depicted in Table 1 . The study protocol was approved by Institutional Review Boards. Recruitment occurred between June 2013 and December 2017. The study data are collected and managed using REDCap software, hosted at Children's Hospital Boston. [36] 
Study procedures
A list with the main clinical and study tests variables are depicted in Tables 2 and 3 . The comprehensive list of study variables is in Appendix 7
Arterial stiffness
CoA treatments alter the biomechanics of the isthmus and may increase arterial stiffness. The velocity of the pulse wave velocity (PWV) travel in the arterial tree increases with arterial stiffness. Carotid-femoral PWV (cfPWV) is extensively validated in large studies a marker of aortic stiffness, and an independent predictor of CV events. [37] We will measure cfPWV with applanation tonometry, using either the NIHem (CV Engineering, Inc., Norwood, MA USA) or the SphygmoCor (AtCor Medical, West Ryde, NSW, Australia) devices. [37] This technique assumes a homogenous stiffness across the aorta and may potentially not accurately estimate the true carotid-to-femoral artery length. Cardiovascular magnetic resonance (CMR) measurements of PWV, on the other way, enables the detection of more subtle changes in segmental aortic PWV, above versus below the CoA site, and uses real aortic travel paths. [38] We will also use CMR to measure aortic area change during the cardiac cycle, paired with BP measurements, to quantify local arterial strain, compliance, distensibility, and the β-stiffness index [Appendix 2a and b].
Endothelial function
In CoA, the loss of central aortic pulsatility, which buffers systole, generates chronic shear stress downstream in smaller arteries, creating endothelial dysfunction, which is associated with CV events. [39] We will measure endothelial function with the reactive hyperemia index using endothelial pulse amplitude tonometry (endo-PAT), a novel noninvasive and reproducible technique that measures changes in pulsatile arterial volume with a fingertip probe. [40] Analysis of the pulse waveform allows for automated calculation of endothelial function in one arm, while the contralateral serves as control, making this is a patient standardized method [Appendix 3].
Pulse waveform analysis
In CoA, the stiff aorta and repaired isthmus may be important reflecting sites that impact the pulse waveform. Its analysis is an important clinical tool for monitoring of vascular function and predicting CV events. [37] We will measure three variables that express pulse waveform: central aortic pressure (CAP), pulse pressure (PP), and augmentation index (AIx; ratio of the amplitude of the reflected wave in the ascending aorta and the PP). [37] CAP, PP, and AIx can be measured noninvasively using applanation tonometry (and Endo-PAT for AIx), calibrated by the peripheral diastolic and mean arterial pressure. [37] There is a lack of consensus regarding the optimal method to estimate the CAP with tonometry. The NIHem system assumes that carotid artery pulse waveform accurately 
Known traditional cardiovascular risk factors
Severe obesity (body mass index >95% for age and sex in children and >40 Kg/m 2 for adults); diabetes (fasting plasma glucose ≥126 mg/dl or random (non-fasting) glucose ≥200 mg/dl); hyperlipidemia (triglycerides≥250 mg/dl; fasting LDL ≥190 mg/dl; HDL ≤30 mg/dl, currently taking statins or first degree relatives with familial hypercholesterolemia); smoking Legend: y=years; BP=blood pressure; CoA=coarctation of the aorta; LDL=low-density lipoprotein cholesterol; HDL=high-density lipoprotein cholesterol; *using highest lower extremity systolic blood pressure; † using previously published normative values [41] Blood pressure phenotype BP phenotype is abnormal despite successful treatment of CoA. Office hypertension is a known risk factor for CV disease and the BP response during the ET is predictive of future development of resting hypertension in the general population. [42] Ambulatory blood pressure monitoring (ABPM) is superior to the office measurement in its ability to distinguish patients at the highest risk for target-organ damage. [43] We will assess BP phenotype with the manual auscultation technique to measure the right arm office BP; supine four extremity oscillometric BP measurement to assess for residual coarctation; ABPM to measure the circadian BP profile; and ET to assess the BP response to exercise and exercise-induced arm to leg BP gradient. Based on the office BP and ABPM results, we will classify our patients according to 
Biomarkers
We will measure asymmetric dimetilarginine (ADMA; NO's inhibitor), [44] and nitrite and nitrate (NOx, stable by-product of NO), biomarkers of endothelial function. Arterial stiffness is associated with increased systemic inflammation markers, which we will quantify with high-sensitivity C-reactive protein (hs-CRP) and local inflammatory cytokines of vascular wall function vascular adhesion molecule 1 (VCAM-1) and interleukin-1 beta (IL-1β). [25, 45] We will finally assess the molecular mechanisms of aortic wall response to vascular dysfunction, with matrix metalloproteases (MMP-2 and MMP-9), [46] and transforming growth factor beta-1 (TGF-β1, a smooth cell growth-modulating factor involved in the arterial wall response to hypertension). [30] NOx will be determined by chemiluminescence (Sievers NOAnalyzer 280i) and all remaining measurements will be performed with enzyme-linked immunosorbent assay kits: ADMA (Sunred Biological Technology, Shanghai, China); hs-CRP (BoosterBio, Pleasanton, USA); VCAM-1; IL-1β; matrix metalloproteases (MMP)-9; MMP-2; and TGFβ-1 (RayBiotech, Inc. Norcross, USA) [Appendix 5].
Left ventricular mass
The altered BP phenotype that persists after CoA treatment represents an increase in afterload that leads to LV hypertrophy, strongly related to high BP and carrying a grave prognosis for cardiac events. [47] We will quantify LV mass by CMR, a well-established method for its calculation [Appendix 2b].
Cardiovascular health assessment
Patients with CoA experience increased CV disease compared to the general population. Literature in the general population has demonstrated that risk of cardiometabolic disease and accelerated atherosclerosis is mitigated by ideal CV health (ICVH), [48] defined as having optimal levels of health factors (BP, total cholesterol, and plasma glucose) and behaviors (smoking, body mass index, physical activity, and diet). We will implement a questionnaire to assess family history of CV disease and ICVH according to the guidelines of the American Heart Association [Appendix 6]. [48] 
Statistical considerations
Adjustment for confounders We will adjust our treatment groups for three main documented confounders: (a) age at treatment; (b) current age; and (c) bicuspid aortic valve (associated with impaired aortic elasticity). [49] During recruitment, we will attempt to frequency match the three treatment groups. During analysis, the treatment groups will be compared for each of these three confounding variables and adjustments will be made using multivariable modeling with linear and logistic regression models.
Analytic plan Our primary outcome variable will be cfPWV assessed by tonometry. Differences across groups will be explored using one-way analysis of variance. If differences in matching variables are detected among the groups, adjustment will be made using analysis of covariance. Post hoc analyses will be performed as necessary. Sample size estimates were obtained based on prior data that show that arch PWV measured by CMR is 3.3 ± 0.6 m/s in normal patients and 4.7 ± 1.1 m/sec after CoA surgery. [20, 50] Sample size estimates for comparison of PVW between three equal-sized treatment groups (assuming overall significance level = 0.05 and power = 0.8) are shown in Table 5 . We plan on recruiting 24-30 patients in each group for a total sample size of 72-90.
DISCUSSION
Methodological considerations
We chose a multicenter design to overcome recruitment challenges secondary to restrictive enrollment criteria (particularly the lower treatment age limit of 1 year, which excludes a majority of CoA patients that present in infancy, mostly managed by surgery) and need for matching treatment groups for confounders. cfPWV is our primary outcome variable because it is validated as an accurate and reproducible measure of arterial stiffness with proven association to hard CV outcomes that can be reliably measured by applanation tonometry and CMR. We chose other parameters to complete a complementary and comprehensive assessment of vascular function in small and large arteries.
Importance of knowledge to be gained
This work will be the first systematic and comprehensive comparison of vascular function between three different treatment modalities in CoA patients. We postulate that the integrity of the arterial wall is best preserved with balloon dilatation, compared to stenting or surgery. We are aware that our population is highly selected, but believe that this is the only way to compare the three treatment types. The results of our selected population may be relevant when several modalities are applicable to one patient. Currently, the preservation of vascular function is not considered when choosing between treatment modalities. Ultimately, the results of our study may help clinicians choose treatment modalities based not only on relief of anatomic stenosis but also on their ability to preserve long-term vascular health.
Study limitations
Our results will reflect vascular function in a selected group of optimally treated CoA patients and may not be generalizable to all CoA patients. We will compare vascular function after treatment but not before the treatment. Variation in antihypertensive medication protocols between different institutions may affect vascular parameters.
CONCLUSION
There is ample evidence to suggest that CoA is a systemic arterial disease and not merely a focal stenosis of the aortic isthmus. However, the current management paradigm continues to focus on alleviating the anatomic stenosis. Our study aims to refine this treatment paradigm by adding the preservation of vascular function to the goals of successful treatment. The strengths of this study include its multicenter design and the use of multiple noninvasive modalities to perform a comprehensive and prospective assessment of vascular function and CV health.
Financial support and sponsorship
The study was supported by two grants, from the Millennium Foundation BCP (awarded on December 18, 2012) and the Fundação Luso-Americana para o Desenvolvimento (Proj A-1 287/2012). [54] ; for adult patients, based on the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure report.
[55] † For pediatric patients, based on normative pediatric ABPM values from the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young; [43] for adult patients, based on the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research report averages during free-breathing will be used. SSFP cine imaging will also be performed in two orthogonal long-axis planes of the left ventricular outflow tract (during breath-hold), short axis of the ascending aorta (AAO), and in the long axis of the aortic arch (free-breathing, used as reference for pulse wave velocity measurements), proximal descending aorta (DAO, 2-3 cm distal to the isthmus, sufficiently distal to dephasing jets), mid-DAO (diaphragmatic level), and distal DAO (just above iliac bifurcation). ECG-gated through-plane phase-contrast flow measurements will be performed at the AAO (5 mm distal to the sinotubular junction) and in proximal-, mid-, and distal-DAO segments (matched to location of the cine SSFP acquisitions) using the following imaging parameters: signal averages = 2, cardiac phases 100 (TFE factor/views per segment/ = 1 [to maximize temporal resolution]), and velocity encoding 200-250 cm/s (higher if needed to avoid aliasing). ECG and respiratory navigator-gated three-dimensional SSFP MRA of the aortic arch will be performed in the sagittal plane.
The patient's right arm BP while on scanner table and length of time since last meal and content of last meal will be recorded. Images will be analyzed by a single observer (A.P.) in the CMR core lab using a commercial computer workstation (Extended Workstation; Philips Healthcare) and using commercially available analysis software (QMass and QFlow, Medis, The Netherlands). Ventricular function and mass will be calculated using standard techniques.
Cross-sectional areas of the AAO and proximal, mid, and distal DAO will be directly planimetered at peak systole and mid-diastolic frames to calculate parameters of segmental aortic stiffness as previously described.
[52] Pulse wave velocity will be measured using the transit-time method.
[20] Pulse wave velocity will be calculated for the entire aorta (AAO to distal DAO), as well as in the following segments: AAO to proximal DAO, proximal DAO to mid-DAO, and mid-DAO to distal DAO. Aortic arch shape will be classified and the aortic arch index calculated as previously described.
[53] Annals of Pediatric Cardiology / Volume 11 / Issue 3 / September-December 2018 be centrifuged at 14,000 rpm for 10 min. The supernatant will be then removed for analysis. The quantification of plasma NO levels will be carried out using a nitric oxide analyzer, the Sievers Instruments NOA 280i TM , a high sensitivity detector of that allows determination of NO based on a chemiluminescence reaction between NO and ozone.
Plasma asymmetric dimetilarginine (ADMA); vascular cell adhesion molecule 1 (VCAM-1); high-sensitivity C-reactive protein (hs-CRP) interleukin-1-beta (IL-1β); MMP-2 and MMP-9 will be quantified using the following double-antibody sandwich enzyme-linked immunosorbent assay ELISA kits: Human asymmetrical dimethylarginine, ADMA (Sunred Biological Technology, Shangai, China); hs-CRP (BoosterBio, Pleasanton, USA); VCAM-1; IL-1β; MMP-9/Gelatinase A; MMP-2/Gelatinase B; and transforming growth factor beta (RayBiotech, Inc. Norcross, USA).
